Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment

Biomaterials

Volumn 34, Issue 8, 2013, Pages 2142-2155

  Fan, Ching Hsiang ^a   Ting, Chien Yu ^a   Liu, Hao Li ^b   Huang, Chiung Yin ^b   Hsieh, Han Yi ^b   Yen, Tzu Chen ^b   Wei, Kuo Chen ^b   Yeh, Chih Kuang ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Antiangiogenic therapy; Blood brain barrier (BBB); Chemotherapy; Focused ultrasound (FUS); Glioblastoma multiforme (GBM); Targeting microbubble

Indexed keywords

ANTI-ANGIOGENIC THERAPY; BLOOD-BRAIN BARRIER; FOCUSED ULTRASOUND; GLIOBLASTOMA MULTIFORME; MICRO-BUBBLE;

BLOOD; CHEMOTHERAPY; DRUG DELIVERY; TOXICITY; ULTRASONICS;

TUMORS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; CONTROLLED STUDY; DISEASE COURSE; DRUG RELEASE; FOCUSED ULTRASOUND; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROBUBBLE; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRASOUND;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; CELL SURVIVAL; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; ETHIDIUM; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; LIVER; MAGNETIC RESONANCE IMAGING; MICROBUBBLES; MICROSCOPY, FLUORESCENCE; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; TOXICITY TESTS; TREATMENT OUTCOME; TUMOR BURDEN; ULTRASONICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 84871488873     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.048     Document Type: Article

References (57)

1. Holland E.C. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000, 97:6242-6244.
2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
3. Arko L., Katsyv I., Park G.E., Luan W.P., Park J.K. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010, 128:1-36.
4. Walker M.D., Alexander E., Hunt W.E., MacCarty C.S., Mahaley M.S., Mealey J., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
5. Brada M., Yung W.K. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 2000, 27:11-19.
6. Hildebrand J., Dewitte O., Dietrich P.Y., de Tribolet N. Management of malignant brain tumors. Eur Neurol 1997, 38:238-253.
7. Loo T.L., Dion R.L., Dixon R.L., Rall D.P. The antitumor agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci 1966, 55:492-497.
8. Erickson L.C., Laurent G., Sharkey N.A., Kohn K.W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980, 288:727-729.
9. Wheeler K.T., Levin V.A., Deen D.F. The concept of drug dose for in vitro studies with chemotherapeutic agents. Radiat Res 1978, 76:441-458.
10. Kornblith P.L., Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988, 68:1-17.
11. Pardridge W.M. Drug and gene delivery to the brain: the vascular route. Neuron 2002, 36:555-558.
12. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986, 46:467-473.
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
14. Gerstner E.R., Batchelor T.T. Antiangiogenic therapy for glioblastoma. Cancer J 2012, 18:45-50.
15. Verhoeff J.J., van Tellingen O., Claes A., Stalpers L.J., van Linde M.E., Richel D.J., et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009, 9:444.
16. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993, 53:5822-5827.
17. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007, 19:2003-2012.
18. Kanno S., Oda N., Abe M., Terai Y., Ito M., Shitara K., et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000, 19:2138-2146.
19. Folkman J. Angiogenesis. Annu Rev Med 2006, 57:1-18.
20. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333:328-335.
21. Wesseling P., Ruiter D.J., Burger P.C. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997, 32:253-265.
22. Sheikov N., McDannold N., Sharma S., Hynynen K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 2008, 34:1093-1104.
23. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646.
24. Vykhodtseva N., McDannold N., Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008, 48:279-296.
25. Ting C.Y., Fan C.H., Liu H.L., Huang C.Y., Hsieh H.Y., Yen T.C., et al. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials 2012, 33:704-712.
26. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000, 267:5421-5426.
27. Mikus J., Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 2000, 48:265-269.
28. Yeh C.K., Chen J.J., Li M.L., Luh J.J., Chen J.J. In vivo imaging of blood flow in the mouse Achilles tendon using high-frequency ultrasound. Ultrasonics 2009, 49:226-230.
29. Liu H.L., Hua M.Y., Chen P.Y., Chu P.C., Pan C.H., Yang H.W., et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010, 255:415-425.
30. Andersen C., Taagehøj J.F., Mühler A., Rehling M. Approximation of arterial input curve data in MRI estimation of cerebral blood-tumor-barrier leakage: comparison between Gd-DTPA and 99mTc-DTPA input curves. Magn Reson Imaging 1996, 14:235-241.
31. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24.
32. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
33. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
34. Kanu O.O., Mehta A., Di C., Lin N., Bortoff K., Bigner D.D., et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009, 13:701-718.
35. Lima F.R., Kahn S.A., Soletti R.C., Biasoli D., Alves T., da Fonseca A.C., et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta 2012, 1826:338-349.
36. Najafi M., Soltanian-Zadeh H., Jafari-Khouzani K., Scarpace L., Mikkelsen T. Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI. PLoS One 2012, 7:e29945.
37. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705.
38. Overvelde M., Garbin V., Dollet B., de Jong N., Lohse D., Versluis M. Dynamics of coated microbubbles adherent to a wall. Ultrasound Med Biol 2011, 37:1500-1508.
39. Suslov S.A., Ooi A., Manasseh R. Nonlinear dynamic behavior of microscopic bubbles near a rigid wall. Phys Rev E Stat Nonlin Soft Matter Phys 2012, 85:066309.
40. Doinikov A.A., Aired L., Bouakaz A. Dynamics of a contrast agent microbubble attached to an elastic wall. IEEE Trans Med Imaging 2012, 31:654-662.
41. Lankford M., Behm C.Z., Yeh J., Klibanov A.L., Robinson P., Lindner J.R. Effect of microbubble ligation to cells on ultrasound signal enhancement: implications for targeted imaging. Invest Radiol 2006, 41:721-728.
42. Ward M., Wu J., Chiu J.F. Experimental study of the effects of Optison concentration on sonoporation in vitro. Ultrasound Med Biol 2000, 26:1169-1175.
43. Kooiman K., Foppen-Harteveld M., van der Steen A.F., de Jong N. Sonoporation of endothelial cells by vibrating targeted microbubbles. J Control Release 2011, 154:35-41.
44. Yang F.Y., Fu W.M., Yang R.S., Liou H.C., Kang K.H., Lin W.L. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. Ultrasound Med Biol 2007, 33:1421-1427.
45. Sheikov N., McDannold N., Vykhodtseva N., Jolesz F., Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 2004, 30:979-989.
46. van Wamel A., Kooiman K., Harteveld M., Emmer M., ten Cate F.J., Versluis M., et al. Vibrating microbubbles poking individual cells: drug transfer into cells via sonoporation. J Control Release 2006, 112:149-155.
47. Meijering B.D., Juffermans L.J., van Wamel A., Henning R.H., Zuhorn I.S., Emmer M., et al. Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ Res 2009, 104:679-687.
48. Huang Q., Deng J., Wang F., Chen S., Liu Y., Wang Z., et al. Targeted gene delivery to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Exp Neurol 2012, 233:350-356.
49. Stupp R., Mason W.P., Van Den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
50. Chahal M., Xu Y., Lesniak D., Graham K., Famulski K., Christensen J.G., et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 2010, 12:822-833.
51. Hsu A.R., Cai W., Veeravagu A., Mohamedali K.A., Chen K., Kim S., et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007, 48:445-454.
52. Nayak T.K., Garmestani K., Baidoo K.E., Milenic D.E., Brechbiel M.W. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A'-DTPA-bevacizumab. Int J Cancer 2011, 128:920-926.
53. Cai W., Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008, 49(Suppl. 2):113S-128S.
54. Gambarota G., Leenders W., Maass C., Wesseling P., van der Kogel B., van Tellingen O., et al. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008, 98:1784-1789.
55. Willmann J.K., Paulmurugan R., Chen K., Gheysens O., Rodriguez-Porcel M., Lutz A.M., et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008, 246:508-518.
56. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
57. Horsman M.R., Bohn A.B., Busk M. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Exp Oncol 2010, 32:143-148.